CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Madrid, Spain and 13 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Madrid, Spain and 66 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Madrid, Spain and 31 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Madrid, Spain and 89 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Madrid, Spain and 73 other locations
immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...
Phase 1
Madrid, Spain and 12 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Madrid, Spain and 186 other locations
to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...
Phase 1
Madrid, Spain and 17 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Madrid, Spain and 56 other locations
JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...
Phase 1
Madrid, Spain and 27 other locations
Clinical trials
Research sites
Resources
Legal